What are the dosing guidelines, contraindications, and precautions for Targin (oxycodone 10 mg/naloxone 5 mg) in an adult without severe hepatic or renal impairment?

Targin (Oxycodone/Naloxone) Dosing and Clinical Guidance

For adults without severe hepatic or renal impairment, Targin should be initiated at 10 mg/5 mg twice daily, with careful titration based on analgesic response and tolerability, recognizing that this combination provides effective analgesia while reducing opioid-induced constipation compared to oxycodone alone. 1

Dosing Guidelines

Initial Dosing

• Starting dose: 10 mg oxycodone/5 mg naloxone twice daily (every 12 hours)
• Tablets must be swallowed whole—never broken, chewed, or crushed
• No food interference with absorption
• Oral administration is the preferred route 1

Titration Strategy

• Increase dose by 25%-50% increments based on pain control and tolerability 2
• Titrate slowly, monitoring for adequate analgesia versus adverse effects
• Provide immediate-release opioids at 5%-20% of total daily morphine equivalent dose for breakthrough pain 2
• Stable plasma levels are reached within 24 hours (faster than morphine's 2-7 days) 3

Dose Adjustments for Mild-Moderate Impairment

Hepatic impairment (mild-moderate):

• Initiate at lower doses than standard
• Oxycodone clearance decreases with hepatic dysfunction
• Oral bioavailability increases significantly due to reduced first-pass metabolism 4, 5
• Critical caveat: In patients with porto-systemic shunting (even with normal liver function tests), naloxone's systemic bioavailability increases, potentially compromising analgesic efficacy 6

Renal impairment (mild-moderate):

• Start at lower doses with careful titration
• Oxycodone is substantially excreted by kidneys; accumulation risk exists 2
• Monitor closely for respiratory depression, sedation, and hypotension 4
• More frequent clinical observation and dose adjustment required 2

Contraindications and Precautions

Absolute Contraindications

• Severe hepatic impairment (avoid Targin due to unpredictable naloxone bioavailability) 6
• Severe renal impairment (oxycodone accumulation risk) 2
• Known hypersensitivity to oxycodone or naloxone
• Respiratory depression or acute/severe bronchial asthma
• Paralytic ileus or suspected mechanical bowel obstruction 7

Critical Precautions

Respiratory Depression Risk:

• Greatest risk in first 24-72 hours after initiation or dose escalation 4
• Elderly patients (≥65 years) have increased sensitivity—start at low end of dosing range 4
• Prescribe naloxone rescue for patients receiving ≥50 morphine milligram equivalents, especially if concurrent benzodiazepines, gabapentinoids, or other sedating agents 2

Hepatic Considerations:

• Even with normal liver function tests, occult porto-systemic shunting can occur with silent cirrhosis, non-cirrhotic portal hypertension, or hepatic metastases 6
• If analgesic efficacy is unexpectedly poor despite adequate dosing, consider unrecognized hepatic impairment affecting naloxone metabolism 6
• Monitor for respiratory depression, sedation, hypotension 4

Drug Interactions:

• Avoid concurrent CYP3A4 inhibitors (increase oxycodone levels)
• Extreme caution with CNS depressants (benzodiazepines, gabapentinoids, alcohol)
• Monitor QTc if using with other QT-prolonging medications

Monitoring Requirements

• First 24-72 hours: Close monitoring for respiratory depression
• Sedation scores in addition to respiratory rate (sedation precedes respiratory depression) 8
• Pain scores at rest and with movement
• Bowel function (Targin reduces but doesn't eliminate constipation risk) 1, 9
• Signs of opioid accumulation in renal/hepatic impairment 2

Advantages of Oxycodone/Naloxone Combination

Reduced constipation: Multiple randomized trials demonstrate that naloxone as a peripherally-acting mu-opioid receptor antagonist reduces opioid-induced constipation while maintaining equivalent analgesic efficacy to oxycodone alone 1, 6, 9

Predictable metabolism: Oxycodone metabolism is more predictable than morphine, making titration easier 3

Efficacy: Studies show effective analgesia with average pain scores of 1/10 at rest and 4/10 on movement, with 81% of patients mobilizing by day 3 post-operatively 9

Common Pitfalls to Avoid

1. Crushing or breaking tablets: This destroys the extended-release mechanism and naloxone's targeted delivery
2. Assuming normal liver function tests exclude porto-systemic shunting: Hepatic metastases, silent cirrhosis, or portal hypertension can increase naloxone bioavailability even with normal labs 6
3. Inadequate breakthrough pain coverage: Always prescribe immediate-release opioids for breakthrough pain during titration 2
4. Neglecting constipation prophylaxis: While Targin reduces constipation versus oxycodone alone, prophylactic laxatives may still be needed 1
5. Rapid titration in elderly or frail patients: Start low, go slow in vulnerable populations 4